Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
ACQUIRED COMPANY
 
My Lists

MAP Pharmaceuticals  (Stock symbol: MAPP ) Acquired by Allergan (2013 $ 958,000,000 )

2400 Bayshore Parkway 2nd Floor
Mountain View, CA 94303
USA
650-386-3100
Website Company Summary Management Team
Board

Outside board: (May no longer be on the board) H Ward Wolff (Sangamo Therapeutics) Matthew V McPherron (Bain Capital Ventures Managing Director) Bernard J Kelley (Merck Manufacturing President) Scott R Ward (Medtronic CardioVascular SVP) W James O'Shea ( Former President/COO) John G Freund (Skyline Ventures Managing Director) Carl Goldfischer (Bay City Capital Managing Director) Gerri A Henwood (Auxilium Pharmaceuticals CEO)
Former outside board: Patrick G Enright (Longitude Capital Managing Director) Steven A Elms (Perseus-Soros BioPharmaceutical Fund Managing Director) Anthony Y Sun (Perseus-Soros BioPharmaceutical Fund Principal)
Former advisory board: Marc-Henri Galletti (Longitude Capital Former Managing Director) Michael S McCord (McCord Investments)
Company

Business description: MAP Pharmaceuticals, Inc. is a specialty pharmaceutical company developing innovative therapies and inhalation delivery platforms to treat a broad spectrum of respiratory and systemic diseases. MAP’s lead product is a proprietary formulation of budesonide for the treatment of pediatric asthma. The Company is also developing a series of respiratory and inhaled systemic drugs based on its Tempo™ Inhaler platform, including a rapid-relief treatment for migraine. Tempo™ is a next generation breath-actuated pMDI that automatically adjusts to different inhalation maneuvers but is exceptionally easy to use, enhancing compliance. Tempo™ also features a novel aerosol flow controller that ensures efficient and consistent delivery of the drug to the lungs, while minimizing oral deposition.
Partners include: Allergan ;  Elan
Capital

Rounds: 4
Recent Fundings: Mar 2007   Jan 2006
Capital raised: 106.5M
Last Round: 50.0M
Ownership: Acquired by Allergan (2013 $ 958,000,000 ) Ipo Filing
Stock Symbol: MAPP

Last Tweets


 

Last Mentions


Overview
Record updated: Dec 2016
Sector: Biotech
Year Founded: 2003
Headcount: 51-75 as of Jun 2008
Rounds: 4
Recent Fundings: Mar 2007   Jan 2006
Capital Raised: 106.5M
Last Round: 50.0M
Ownership: Acquired by Allergan (2013 $ 958,000,000 ) Ipo Filing
Stock Symbol: MAPP